Global Keratoconjunctivitis sicca (Dry Eye) Market -Pipeline Review, H2 2017

“The Latest Research Report Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

About Keratoconjunctivitis sicca Market

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H2 2017, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline landscape.

Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS) or keratitis sicca, is a multifactorial disease of the tears and the ocular surface that results in discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. Symptoms include eye fatigue, sensitivity to light, eye redness and stringy mucus in or around eyes. Risk factors include age, having laser eye surgery and taking medications that can cause dry eyes.

Get Sample copy of this Report @

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis sicca (Dry Eye)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 20, 9, 1, 24, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

View Sample PDF @


– The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).

– The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Send An Enquiry Request @

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Keratoconjunctivitis sicca (Dry Eye)-Overview 9

Keratoconjunctivitis sicca (Dry Eye)-Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 20

Keratoconjunctivitis sicca (Dry Eye)-Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 24

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Keratoconjunctivitis sicca (Dry Eye)-Companies Involved in Therapeutics Development 31

Alcon Laboratories Inc 31

Aldeyra Therapeutics Inc 31

Allergan Plc 31

Ascendia Pharmaceuticals LLC 32

BioLineRx Ltd 32

Cambium Medical Technologies LLC 33

Chong Kun Dang Pharmaceutical Corp 33

Clementia Pharmaceuticals Inc 34

Dompe Farmaceutici SpA 34

Elasmogen Ltd 34

HanAll Biopharma Co Ltd 35

Herantis Pharma Plc 35

Huons Global Co Ltd 36

InSite Vision Inc 36

Kala Pharmaceuticals Inc 37

KPI Therapeutics Inc 37

Kukje Pharmaceutical Industry Co Ltd 37

Laboratoires Thea SA 38

Lipicard Technologies Ltd 38

Merck & Co Inc 38

Mitotech SA 39

Nanomerics Ltd 39

Nemus Bioscience Inc 40

Novaliq GmbH 40

Ocular Therapeutix Inc 40

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074



Designed by
Powered by
%d bloggers like this: